A Primer for Orthopedic Surgeon-Product Representative Relationships

Introduction

The introduction of orthopedic product representatives (OPRs) into the operating room (OR) dates back to the mid-20th century, coinciding with the development of prosthetic implants and biocompatible materials. ¹ As orthopedic surgery and implant technology have become increasingly complex, the role of OPRs has evolved: from marketing and commercial agents to clinical companions who provide technical support and device troubleshooting in the OR.^2,3 Consequently, many surgeons see OPRs as an extension of the surgical team.

Studies have shown that this partnership has advanced orthopedic care by expanding treatment options and enhancing outcomes,^1,2 yet it is a relationship marked by a complex blend of interests. ⁴ The orthopedic surgeon’s primary concern is the patient’s welfare, while the OPR has a dual role: a technical specialist aligned with patient care and a sales agent aligned with commercial profits. ⁴ Beyond potential financial conflicts, the presence of OPRs in the OR raises questions about patient safety, autonomy, and professional boundaries.^3,5 In some instances, surgical teams rely on OPRs for intraoperative product guidance beyond their intended role, raising concerns about accountability. ³ These concerns extend to potential legal liability, including claims related to intraoperative guidance and invasion of privacy arising from lack of informed consent when OPRs are present in the operating theater.

Despite the recognized clinical value and ethical and legal risks in the surgeon-OPR dynamic, the orthopedic community lacks a contemporary primer that consolidates the professional, ethical, legal, and regulatory structures overseeing this relationship in the United States. Therefore, this commentary aims to examine the surgeon-OPR relationship by (1) outlining its historical evolution and current clinical functions; (2) analyzing ethical challenges; (3) reviewing applicable legal and regulatory frameworks; and (4) synthesizing recommendations and future models to preserve decision-making integrity and prioritize patient outcomes.

AI Use Disclosure: The artificial intelligence tool Claude (Anthropic) was used to assist with literature searching. All content was reviewed and verified by the authors.

The Evolution of OPRs

In the mid-20th century, orthopedic surgeons began collaborating with industry partners to meet specific clinical needs. This partnership was initially surgeon-led; innovation in product creation and use was determined by the surgeon’s techniques and preferences. ¹ Over time, industry involvement expanded beyond product development to include medical education and research, ⁴ producing a symbiotic model in which industry emphasizes innovation and market leadership, while surgeons prioritize efficiency, professional identity, and clinical viability. However, these opposing views were coupled with the goal of improving patient outcomes and patient care throughput. ⁴ As industry involvement expanded, surgeons were exposed to medical devices earlier in their careers, including during residency training. ⁶ Earlier exposure to medical devices through cadaver and sawbone training shapes long-term adoption patterns. ⁶

Today, the role of OPRs has shifted from a primarily commercial function to one of intraoperative technical support. OPRs possess knowledge of implant systems, surgeon preferences, and operative workflows, enabling technical assistance. ² OPRs can help the surgical team complete a case more efficiently by providing real-time device guidance and support during operative procedures. ⁷

Current Role and Scope in the OR

In a 2017 survey of 127 orthopedic trauma surgeons, OPRs were seen as an integral component of the modern OR, with many surgeons reporting that they are needed for operative procedures. ⁸ This integration reflects growing reliance on their expertise in product management, surgical efficiency, and setup accuracy. However, institutional policies governing OPR participation in the OR is not standardized across healthcare systems, creating variability in oversight and role definition. This raises concerns and potential conflicts of interest about accountability, training, and the ethical boundaries of OPRs in the OR.

Several studies have described medical device representatives as managing surgical trays, confirming implant availability, and troubleshooting equipment issues during operative procedures. Their early presence in the OR supports instrument preparation and contributes to operative workflow efficiency.^2,6 Their knowledge of their company’s product surpasses that of others in the room, other than the surgeons using them. Increasing responsibility and reliance have blurred the boundary between technical support and commercial influence. Given the frequency and depth of their involvement in the OR, OPRs are seen by many surgeons as essential collaborators. Their presence has been associated with improvements in operative efficiency and perceived satisfaction among both surgeons and patients. ⁷ However, others view this proximity with caution, citing ethical concerns related to transparency, patient awareness and consent, and the potential for commercial influence in a clinical environment where OPRs are not formally recognized as members of the surgical team. ⁹ Such concerns raise questions about conflicts of interest, especially when the representative’s role is commercial rather than clinical and when reports describe nondisclosure of product defects or recalls. ⁹

Professional and Ethical Considerations

Vendor-surgeon dynamics have extended beyond those of a consumer relationship to encompass professional choices and ethical frameworks. Many orthopedic surgeons have formed long-term relationships with single vendors for their implants and medical devices via early exposure in their medical education and reinforced through consulting agreements.^6,10 The loyalty of the surgeon to the vendor can cause difficulties in cost-implementation strategies from hospitals as they try to balance profitability with surgeon satisfaction. A 2020 survey of 59 shoulder surgeons found that the surgeons valued the vendors for qualities such as attentiveness and product knowledge in the OR and that vendor behavior and professionalism influenced the implant choices that they made. ⁷ This dynamic raises ethical concerns when patients remain unaware of the representative’s role while clinical decisions may be influenced by nonclinical factors.

To combat the lack of transparency and mitigate the influence that OPRs may have on surgeons, the American Academy of Orthopedic Surgeons (AAOS) has implemented Standards of Professionalism (SOP) meant to encourage that a consulting arrangement between vendor and surgeon is transparent, merit-based, and centered on patient care. ¹¹ Surgeons are required to disclose any financial ties to institutions and patients to help with informed consent. ¹² Due to the fact that these disclosures are largely self-reported, conflicts of interest may persist. This allows OPRs to continue operating as they have within the OR and in the realm of patient care.

Most patients presume that their operative care is delivered by the surgical team with clinical training and may not anticipate the participation of third-party personnel in the OR. OPRs providing intraoperative guidance or failing to disclose device-related limitations creates potential risks to patient safety and professional accountability. These concerns are compounded by financial relationships and the appropriate boundaries of industry involvement in operative care.^11,12

Despite SOPs being in place, most residency programs still lack infrastructure for managing vendor relationships within graduate medical education. ¹⁰ Thus, trainees may be insufficiently aware of the subtle pressures exerted by seasoned OPRs, potentially allowing their clinical preferences and decisions to be shaped by commercial influences. In academic environments, financial relationships between orthopedic surgeons and industry are well documented and increasingly scrutinized because of concerns regarding transparency and public trust. ¹³

Legal and Regulatory Framework

As orthopedic technology advances, the U.S. Food and Drug Administration’s 510(k) pathway has become the primary mechanism for device clearance. However, devices cleared through this pathway often reach the market without extensive supporting clinical data. ¹⁴ Notably, many Class I recalls—of devices posing serious health risks—were cleared through the 510(k) pathway. ¹⁴ This raises a question: how do newly cleared devices achieve rapid intraoperative adoption despite limited supporting evidence? In practice, OPRs frequently bridge this gap by providing device-specific instruction at the point of care, sometimes in settings where supporting clinical data are limited. ¹⁵

The Stark Law restricts physician referral to entities with which they have financial relationships to reduce biased clinical decision-making. ¹⁶ The Anti-Kickback Statute follows the same sentiment. ¹⁶ Despite these protections, patient awareness of surgeon-industry relationships and third-party presence in the OR remains inconsistent. The Physician Payment Sunshine Act mandates disclosure of industry relationships; however, many surgeons do not routinely inform patients of the presence of OPRs in the OR. ¹⁷ Despite federal statutes and professional guidelines, transparency and enforcement remain uneven. Recent analyses published in JAMA identified orthopedic surgery as the specialty receiving the greatest total industry payments among U.S. physicians, reinforcing the importance of transparency and oversight in surgeon-industry relationships. ¹⁸

Although transparency policies aim to address surgeon-industry relationships, their impact on patient perception appears limited. More recent evidence suggests that disclosure of physician-industry payments may negatively influence perception of individual physician honesty and fidelity, particularly when larger payments are involved. In a 2017 randomized experimental study evaluating public disclosure of physician-industry payments, physicians receiving larger industry payments were perceived as less honest and less committed to patients’ best interests compared with physicians receiving no payments. ¹⁹ However, disclosure did not significantly alter trust in the medical profession or in the pharmaceutical and medical device industry overall. ¹⁹ Conversely, a 2016 systematic review found that most patients believed such relationships either improved or did not adversely affect their care and trusted surgeons to act in their best interest regardless of financial ties. ²⁰ These findings suggest that transparency remains an important ethical consideration while patient perceptions of surgeon-industry partnerships remain complex and multifactorial.

Best Practices and Professional Guidelines

The AAOS SOPs stipulate that orthopedic surgeons’ primary responsibility is to the patient, that a surgeon’s financial relationships relevant to a patient’s care be disclosed, and that payments or incentives to surgeons tied to product use or sales be prohibited. ¹¹ Additionally, consulting arrangements must be based on fair market value, documented need, and legitimate services. Although collaboration between surgeons and industry advances device development and innovation, such collaborations must be structured to preserve clinical independence. ¹¹ When representatives are present in the OR, surgeons are responsible for ensuring that participation enhances patient safety, respects patient autonomy and confidentiality, complies with institutional policies, and does not extend beyond the representative’s training or scope. ⁵ The American College of Surgeons recommends institutional oversight, formal credentialing, education in perioperative standards, and explicit patient notification when healthcare industry representatives are present in the OR. ²¹

It is important to recognize that OPRs provide perioperative technical instruction to the surgical team, but their participation must not replace the surgeon’s responsibility to obtain adequate training and demonstrate competence in device use before a procedure in the OR. Accordingly, representatives should function strictly as technical educators and facilitators, without engaging in direct patient care, medical decision-making, or unsupervised intraoperative activity. ²¹

Moreover, it is reasonable to expect that an OPR, as a de facto member of the surgical team, upholds the same ethical commitment to patient safety as all other team members. This duty is primarily expressed through educating and supporting the surgeon during procedural preparation. ¹² However, because representatives’ compensation may depend on maintaining positive relationships with surgeons, ethical tensions may arise when concerns regarding a surgeon’s familiarity with a device or procedural preparedness intersect with commercial interests.

In summary, the presence of OPRs in surgical practice remains an important yet complex aspect of modern orthopedics. Their familiarity with devices can enhance procedural efficiency, but professional boundaries and institutional oversight must be clearly defined to limit inherent conflicts of interest. As surgical technology continues to advance, surgeons and health systems bear responsibility for developing and maintaining policy frameworks that protect clinical autonomy and ensure patient welfare remains the central priority.

Supplemental Material

Supplemental Material

Supplemental Material

Supplemental Material